← Back to Search

Not Applicable

BI 690517 for Chronic Kidney Disease

Phase 2
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 weeks
Awards & highlights

Study Summary

This trial is looking at whether BI 690517, with or without empagliflozin, can improve kidney function in people with chronic kidney disease.

Eligible Conditions
  • Chronic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from treatment period baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in First Morning Void urine
Secondary outcome measures
UACR response I, defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline
UACR response II, defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment period: Placebo to Empagliflozin + BI 690517Experimental Treatment1 Intervention
Group II: Treatment period: Empagliflozin + Placebo to BI 690517Experimental Treatment2 Interventions
Group III: Treatment period: Empagliflozin + BI 690517Experimental Treatment2 Interventions
Group IV: Treatment period: Placebo to Empagliflozin + Placebo to BI 690517Placebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BI 690517
2017
Completed Phase 2
~1040
Placebo to BI 690517
2022
Completed Phase 2
~720
Empagliflozin
2017
Completed Phase 4
~181750

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,505 Previous Clinical Trials
11,339,578 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial taking place in several different hospitals across Canada?

"This trial has 52 enrolling patients with locations including Amicis Research Center in Northridge, Knoxville Kidney Center PLLC in Knoxville, and Sameh Fikry Medicine Professional Corporation in Waterloo."

Answered by AI

How many people can sign up for this clinical trial in total?

"The sponsor, Boehringer Ingelheim, needs 552 eligible patients in order to carry out the study across multiple sites, such as Amicis Research Center in Northridge, California and Knoxville Kidney Center PLLC in Knoxville, Tennessee."

Answered by AI

Are people still being signed up for this experiment?

"The clinical trial is recruiting participants, as seen on clinicaltrials.gov. The study was originally posted on 1/11/2022 and has had one update on 11/14/2022."

Answered by AI

Has BI 690517 been cleared for public consumption in the United States?

"There is some data suggesting BI 690517 is safe, but none yet affirming that it is effective. Consequently, we have given it a 2."

Answered by AI

Who else is applying?

What state do they live in?
Washington
Florida
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
What site did they apply to?
Recherche GCP Research
National Nephrology Alliance Research
Triad Internal Medicine

Why did patients apply to this trial?

I’ve presently take blood pressure medication along with jardiance. My kidney function is 47%. I believe that the 690517 is going to really help people like me.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
2022. "A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05182840.
~220 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top